Health Care • Biotechnology: Pharmaceutical Preparations
$1.75 ▼ -0.46
(-20.81%)
MKT CAP: $26.5M • VOL: 1.17M
52W L $2 52W H $10
ROARABLE / RQD
E • 29/100
PIOTROSKI
2 / 9
CRVO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.0M | $9.7M | $7.1M |
| YoY Revenue Growth % | -58.9% | +36.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$28.3M | -$18.2M | -$7.8M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$27.0M | -$16.3M | -$2.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.4M | -$16.5M | -$7.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$23.4M | -$16.5M | -$7.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.2M | $9.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $18.2M | $39.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRVO.